{"id":"545e23db-52ad-5207-9b12-5f49bcae6ade","stable_key":"5d8e27d8-6a74-5560-827f-3f90908bbc34:ala-nathan1-primary-null","predicate":"did_not_significantly_improve","statement":"NATHAN 1 did not show a significant ALA effect on its prespecified NIS-LL plus seven-test primary composite at four years (P=0.105).","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"neutral","is_public":true,"mechanism_event_id":"c8e6cadc-44cb-58eb-b627-df5131960b96","mechanism_event_label":"The long trial did not meet its main efficacy endpoint.","subject":{"id":"ab091982-3acb-5a87-80fb-85dfe292c1e0","slug":"lipoic-acid","display_name":"Lipoic acid","entity_type_key":"small_molecule"},"object":{"id":"72c4e878-0139-553c-ba21-bfbee40cafd6","slug":"nathan1-primary-composite","display_name":"NATHAN 1 NIS-LL plus seven neurophysiological-test composite","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"c8e6cadc-44cb-58eb-b627-df5131960b96","stable_key":"5d8e27d8-6a74-5560-827f-3f90908bbc34:ala-nathan1-primary-null-event","event_type":"observed_intervention","label":"The long trial did not meet its main efficacy endpoint.","description":"NATHAN 1 did not show a significant ALA effect on its prespecified NIS-LL plus seven-test primary composite at four years (P=0.105).","status":"provisional","compartment":null,"participants":[{"entity":{"id":"ab091982-3acb-5a87-80fb-85dfe292c1e0","slug":"lipoic-acid","display_name":"Lipoic acid","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"72c4e878-0139-553c-ba21-bfbee40cafd6","slug":"nathan1-primary-composite","display_name":"NATHAN 1 NIS-LL plus seven neurophysiological-test composite","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/ala-research/21775755.abstract.txt\", \"locator\": \"Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"39d87bd4d8c5b80564bce0fd04c3c62d00b5c76e8edac29d94ff176b97bcc1f9\", \"start_char\": 0, \"end_char\": 1839, \"text_sha256\": \"39d87bd4d8c5b80564bce0fd04c3c62d00b5c76e8edac29d94ff176b97bcc1f9\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"NATHAN 1 randomized placebo-controlled trial","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"ALA 600 mg/day for four years","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Primary endpoint and secondary analyses must remain distinct; lack of expected placebo deterioration complicated interpretation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Alpha-lipoic acid research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"lipoic-acid","display_name":"Lipoic acid","entity_type_key":"small_molecule"}},{"dimension":"organism","value_text":"Human","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"The long trial did not meet its main efficacy endpoint.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[ala-p21775755] Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. (2011). https://pubmed.ncbi.nlm.nih.gov/21775755/ DOI: 10.2337/dc11-0503","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"460 people with mild-to-moderate diabetic polyneuropathy","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"4a743d0d-d7e6-51b9-8c8d-7a23bc0dd308","evidence_kind":"source_excerpt","locator":"Lines 1170-1181","start_line":1170,"end_line":1181,"excerpt":"### ala-nathan1-primary-null\nNATHAN 1 did not show a significant ALA effect on its prespecified NIS-LL plus seven-test primary composite at four years (P=0.105).\nCondition category: normal\nnutrient_topic: Alpha-lipoic acid research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: The long trial did not meet its main efficacy endpoint.\norganism: Human\ntissue_or_cell_type: 460 people with mild-to-moderate diabetic polyneuropathy\nexperimental_model: NATHAN 1 randomized placebo-controlled trial\nlimitations: Primary endpoint and secondary analyses must remain distinct; lack of expected placebo deterioration complicated interpretation.\nexposure: ALA 600 mg/day for four years\nevidence_span: {\"source_cache\": \"artifacts/ala-research/21775755.abstract.txt\", \"locator\": \"Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"39d87bd4d8c5b80564bce0fd04c3c62d00b5c76e8edac29d94ff176b97bcc1f9\", \"start_char\": 0, \"end_char\": 1839, \"text_sha256\": \"39d87bd4d8c5b80564bce0fd04c3c62d00b5c76e8edac29d94ff176b97bcc1f9\"}\n[ala-p21775755] Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. (2011). https://pubmed.ncbi.nlm.nih.gov/21775755/ DOI: 10.2337/dc11-0503","model_system":"NATHAN 1 randomized placebo-controlled trial","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [ala-p21775755] Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. (2011). https://pubmed.ncbi.nlm.nih.gov/21775755/ DOI: 10.2337/dc11-0503","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"d8afa8c2-ced9-5b28-90ca-2ac120ec7202","stable_key":"import-5d8e27d8-6a74-5560-827f-3f90908bbc34","title":"Alpha-lipoic acid: cofactor assembly, redox signaling and nutrient interactions (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"611da198ab85a272eb26b64ee330ef6d1a762853a8481f3191c4acfca9f3cf3d","revision_id":"618b4ce6-3157-5222-8325-408064be5ea5","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}